moneyheap
MDT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Medtronic plc (MDT) stock moving?
Medtronic has had a constructive two weeks. The SPYRAL AFFIRM six-month blood pressure data and the FDA labeling update (Nov 3) were followed by a sharp move: the stock rose from $98.88 to $104.96 on Nov 4 on 11.6M shares, about 1.3 times the recent average, and reached $106.20 on Nov 5 on similar volume. The news list does not state what drove the Nov 4 move, so the link to SPYRAL is an observed timing, not a confirmed cause. Since then the stock has eased to $101.59 on Nov 10, about 4% below the Nov 5 high, while volume fell to 5.05M, suggesting the buying pressure has faded. The close sits near the $101.47 VWAP, so the stock is trading around its recent average price. Overall, the stock is up about 8% from the $93.95 close on Oct 27. Analyst sentiment has improved: Bank of America raised its target to $120 from $110 on Nov 9 and kept its bullish rating. Other news is supportive but minor: the Recor renal denervation real-world evidence, the OrthoPediatrics launch using Medtronic-licensed technology, and an Orchestra BioMed TCT presentation. The next major catalyst is fiscal Q2 2027 results on Nov 24, 2026, which is outside the 7-day window. The 8-K filed Oct 19 (for an Oct 15 event) shows only its cover page and debt-security exhibits in the provided text, so it does not add a usable business driver. Key risks are the post-spike pullback, fading volume, and the unknown earnings outcome.
News behind the analysis
- Bank of America Securities Raises Medtronic Price TargetBank of America Securities analyst Travis Steed kept a bullish rating on Medtronic and raised the price target from $110 to $120.
- Medtronic Reports Positive SPYRAL AFFIRM Study Results and FDA Labeling UpdateMedtronic reported significant six-month blood pressure reductions in the SPYRAL AFFIRM study and received FDA approval for a labeling update that includes these data.
- Medtronic Schedules Second Quarter Fiscal Year 2027 Financial Results AnnouncementMedtronic will report fiscal Q2 2027 financial results on November 24, 2026.
- Medtronic and Recor Medical Report Real-World Evidence for Renal DenervationMedtronic and Recor Medical released new real-world evidence on the clinical performance of their renal denervation technology.
- OrthoPediatrics Launches VerteGlide System Utilizing Medtronic Licensed TechnologyOrthoPediatrics introduced the VerteGlide Spinal Growth Guidance System, which incorporates Shilla technology licensed from Medtronic.
- Orchestra BioMed Provides Update on Medtronic Collaboration for AVIM TherapyOrchestra BioMed said its Virtue Sirolimus AngioInfusion Balloon, developed with Medtronic, will be featured at the TCT 2026 conference.
- Medtronic and Michael J. Fox Foundation Partner on Parkinson's Deep Brain Stimulation EducationMedtronic partnered with the Michael J. Fox Foundation to improve patient understanding of deep brain stimulation therapy for Parkinson's disease.
- Medtronic Stroke Care Technology Highlighted in Patient Recovery StoryA patient recovery story describes a successful mechanical thrombectomy using Medtronic's Solitaire X Revascularization Device.
- Medtronic Advances Wildlife Conservation Research with Cardiac Monitoring TechnologyMedtronic is donating LINQ insertable cardiac monitors to track heart activity in various animal species for conservation research.
About Medtronic plc
Medtronic is one of the world's largest medical device makers, selling heart, surgical, spine, brain and other therapy devices to hospitals and doctors in roughly 150 countries; it is legally based in Ireland and its shares trade on the NYSE. It is known for its very broad product range and a long record of raising its dividend (close to 50 years in a row). In October 2026 it finished spinning off its diabetes business as a separate company, MiniMed (MMED).
How it makes money
Medtronic sells medical devices and related therapies, mostly to hospitals and health systems. Revenue for fiscal 2026 (the year ending April 2026) was about $36 billion, and that figure still included diabetes. It has four main areas. Cardiovascular, its largest at roughly a third of sales, covers pacemakers, defibrillators, heart-rhythm ablation tools including pulsed-field ablation, heart valves and renal denervation. Neuroscience covers spine, neuromodulation and cranial devices. Medical Surgical covers surgical tools, staplers and robotic surgery. Diabetes products, roughly a tenth of sales, left with the MiniMed spin-off in October 2026. About half of revenue comes from the US.
What usually moves MDT
- Growth of cardiac ablation (pulsed-field) and other heart products
- New products winning approval and insurance payment, e.g. renal denervation and the Hugo surgical robot
- Hospital procedure volumes and spending
- Currency swings, tariffs and supply-chain or quality issues
- Effects of the MiniMed spin-off and changes to its product mix